Sinopharm Unit Denies Ties with Human Remains Scandal

Sinopharm subsidiary China National Medicines announced it has no business relationships with Shanxi Osteorad Biomaterial Co. Shanxi Osteorad is under suspicion for the illegal purchase of human remains and limbs for producing allogeneic bone implantable materials, as reported by government-backed media The Paper.

Sinopharm subsidiary China National Medicines declared on Friday that it does not engage in any business dealings or maintain relations with Shanxi Osteorad Biomaterial Co. The statement was made via a filing to the Shanghai Stock Exchange.

Shanxi Osteorad Biomaterial Co. is currently under investigation for allegedly purchasing human remains and limbs illegally. These materials were reportedly intended for the production of 'allogeneic bone implantable materials,' according to reports from government-backed media outlet The Paper.

The ongoing investigation has raised significant ethical and legal concerns in the biomedical industry.

(With inputs from agencies.)